Cimeio Therapeutics
Reinventing cell therapy through our leadership in the emerging field of epitope shielding
Reinventing cell therapy through our leadership in the emerging field of epitope shielding
Cimeio Therapeutics is a rapidly emerging player in the biopharma, biotechnology, and health care industries. Established in 2020 and headquartered in the United States, the company's slogan "Reinventing cell therapy through our leadership in the emerging field of epitope shielding" succinctly captures its innovative approach. Cimeio Therapeutics is focused on developing Shielded-Cell & Immunotherapy Pairs, leveraging its proprietary technology platform centered on protein variants, to create curative treatments for patients suffering from genetic diseases, hematologic malignancies, and severe autoimmune disorders. The company recently secured a significant milestone with a $50.00M Series A investment led by Versant Ventures in April 13, 2022. This latest investment puts them in a strong position to advance their pioneering research and development efforts, positioning them as a compelling investment opportunity within the rapidly evolving field of cellular and gene-based therapies. Cimeio Therapeutics stands out for its potential to bring transformational therapies to patients facing serious and life-threatening diseases, making it a compelling prospect for investors seeking to support disruptive advancements in the healthcare space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $50.00M | 1 |
|
13 Apr 2022 |
No recent news or press coverage available for Cimeio Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.